Strategies for developing effective radioimmunotherapy for solid tumors

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  DeNardo, Gerald L ^a,b   O'Donnell, Robert T ^a   Kroger, Linda A ^a   Richman, Carol M ^a   Goldstein, Desiree S ^a   Shen, Sui ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CATHEPSIN; CELL SURFACE PROTEIN; IODINE 131; MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN P53; RADIOISOTOPE; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; YTTRIUM 90;

APOPTOSIS; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SOLID TUMOR;

ANIMALS; BONE MARROW TRANSPLANTATION; CHELATING AGENTS; HUMANS; MICE; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 0032697131     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhard, J. A., Janakiraman, N., Foon, K. A., Liles, T-M., Dallaire, B. K., Wey, K., Royston, I., Davis, T., and Levy, R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90: 2188-2195, 1997.
2. Baselga, J. U., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neuoverexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
3. DeNardo, G. L., O'Donnell, R. T., and DeNardo, S. J. A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother. Radiopharm., 13: 213-223, 1998.
4. Begent, R. H., Ledermann, J. A., Green, A. J., Bagshawe, K. D., Riggs, S. J., Seagle, F., Keep, P. A., Adam, T., Dale, R. G., and Glaser, M. G. Antibody distribution and dosimetry in patients receiving radio-labeled antibody therapy for colorectal cancer. Br. J. Cancer. 60: 406-412, 1989.
5. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., Plott, W. E., Grizzle, W. E., Wheeler, R. H., Schlom, J., Russell, C. D., Liu, T., LoBuglio, A. F., Saleh, M. N., Allen, L. F., Orr, R. A., Colcher, D., and Shochat, D. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J. Nucl. Med., 33: 23-29, 1992.
6. 131I-CC49 in colorectal cancer. Cancer (Phila.), 73: 1057-1066, 1994.
7. 90Y-CYT-356 monoclonal antibody. Clin. Cancer Res., 2: 1289-1297, 1996.
8. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Vagg, R. C., Ying, Z., Zhang, C. H., Swayne, L. C., Vardi, Y., Siegel, J. A., and Goldenberg, D. M. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J. Nucl. Med., 38: 858-870, 1997.
9. DeNardo, S. J., O'Grady, L. F., Richman, C. M., Goldstein, D. S., O'Donnell, R. T., DeNardo, D. A., Kroger, L. A., Lamborn, K. R., Hellstrom, K. E., Hellstrom, I., and DeNardo, G. L. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res., 17: 1745-1752, 1997.
10. DeNardo, G. L., Kroger, L. A., DeNardo, S. J., Miers, L. A., Salako, Q., Kukis, D. L., Fand, I., Shen, S., Renn, O., and Meares, C. F. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer (Phila.), 73: 1012-1022, 1994.
11. Adams, G. P. Improving the tumor specificity and retention of antibody-based molecules. In Vivo, 72:11-22, 1998.
12. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G. M., Fisher, L. D., Porter, B., Matthews, D. C., and Bernstein, I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.
13. Moi, M. K., Meares, C. F., and DeNardo, S. J. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetra-azacylododecane N,N′,N[dprime,N‴-tetraacetic acid and study of its yttrium (III) complex. J. Am. Chem. Soc., 110: 6266-6267, 1988.
14. DeNardo, S. J., Richman, C. M., Goldstein, D. S., Shen, S., Salako, Q. A., Kukis, D. L., Meares, C. F., Yuan, A., Welborn, J. L., and DeNardo, G. L. Yttrium-90/Indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res., 17: 1735-1744, 1997.
15. 90Y MAB 170H.82 with autologous stem cell support and cyclosporin A. Clin. Cancer Res., 5 (Suppl.): 3243s-3248s, 1999.
16. Sharkey, R. M., Motta-Hennessy, C., Pawlyk, D., Siegel, J. A., and Goldenberg, D. M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonie tumor xenografts. Cancer Res., 50: 2330-2336, 1990.
17. DeNardo, S. J., Zhong, G-R., Salako, Q., Li, M., DeNardo, G. L., and Meares, C. F. Pharmacokinetics of chimeric L6 conjugated to indium-111 and yttrium-90-DOTA-peptide in tumor bearing mice. J. Nucl. Med., 36: 829-836, 1995.
18. Li, M., and Meares, C. F. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjugate Chem., 4: 275-283, 1993.
19. DeNardo, G. L., Kroger, L. A., Meares, C. F., Richman, C. M., Salako, Q. A., Shen. S., Lamborn, K. R., Peterson, J. J., Miers, L. A., Zhong, G. R., and DeNardo, S. J. Comparison of DOTA-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2IT-BAD-ChL6 in breast cancer xenografts. Clin. Cancer Res., 4: 2483-2490, 1998.
20. Press, O. W., Shan, D., Howell-Clark, J., Eary, J., Appelbaum, F. R., Matthews, D., King, D. J., Haines, A. M., Hamann, P., Hinman, L., Shochat, D., and Bernstein, I. D. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res., 56: 2123-2129, 1996.
21. Peterson, J. J., and Meares, C. F. Cathepsin substrates as cleavable peptide linkers on bioconjugates. selected from a fluorescence quench combinatorial library. Bioconjugate Chem., 8: 618-626, 1998.
22. Peterson, J. J., Pak, R. H., and Meares, C. F. Total solid-phase synthesis of DOTA-functionalized peptides for radioimmunotherapy. Bioconjugate Chem., 10: 316-320, 1999.
23. Frei, F., Amman, K., Teicher, B., Eder, P., and Schnipper, L. Bone marrow autotransplantation for solid tumors: prospects. J. Clin. Oncol., 7: 515-526, 1998.
24. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J. Clin. Oncol., 16: 3246-3256, 1998.
25. Cagnoni, P. J., Shpall, E. J., Bearman, S. I., Matthes, S., Ross, M., Taffs, S., and Jones, R. B. Paclitaxel-containing high-dose chemotherapy: The University of Colorado experience. Semin. OncoL, 23: 43-48, 1996.
26. Wong, J. Y., Williams, L. E., Yamauchi, D. M., Odom-Maryon, T., Esteban, J. M., Neumaier, M., Wu, A. M., Johnson, D. K., Primus, F. J., and Shively, J. E. Initial experience evaluating yttrium-90-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a Phase I radioimmunotherapy trial. Cancer Res., 55: 5929-5934, 1995.
27. Macklis, R. M., Beresford, B. A., Palayoor, S., Sweeney, S., and Humm, J. L. Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int. J. Radiat. Oncol. Biol. Phys., 27: 643-650, 1993.
28. 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model. Clin. Cancer Res., 5 (Suppl.): 3010s-3014s, 1999.
29. 2/M-phase block and other radiobiological parameters. Radiat. Res., 135: 24-31, 1993.
30. Horwitz, S. B. Mechanism of action of Taxol. Trends. Pharmacol. Sci., 13: 134-136, 1992.
31. Choy, H., Akerley, W., Glantz. M., Safran, H., Graziano, S., and Chung, C. Concurrent paclitaxel and radiation therapy for solid tumors. Cancer Control, 3: 310-318, 1996.
32. Liebmann, J., Cook, J. A., Fisher, J., Teague, D., and Mitchell, J. B. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). Int. J. Radiat. Oncol. Biol. Phys., 29: 559-564, 1994.
33. 177Lu-CC49. Minerva Biotechnologica. 10; 100-107, 1998.